# EDGAR Filing Document

**Accession Number:** 0001539029
**File Stem:** 0001193125-25-297177
**Filing Date:** 2025-11
**Character Count:** 25582
**Document Hash:** 01d3cf2c45d5f113d65c82906c128314
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-297177.hdr.sgml**: 20251125

**ACCESSION NUMBER**: 0001193125-25-297177

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251123

**ITEM INFORMATION**: Bankruptcy or Receivership

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251125

**DATE AS OF CHANGE**: 20251125

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Clearside Biomedical, Inc.
- **CENTRAL INDEX KEY:** 0001539029
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452437375
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37783
- **FILM NUMBER:** 251521072

**BUSINESS ADDRESS:**
- **STREET 1:** 900 NORTH POINT PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30005
- **BUSINESS PHONE:** 678-270-3631

**MAIL ADDRESS:**
- **STREET 1:** 900 NORTH POINT PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30005

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): November 23, 2025

## Clearside Biomedical, Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37783** | **45-2437375** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **900 North Point Parkway**<br> **Suite 200** |  |
| **Alpharetta, Georgia** | **30005** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (678) 270-3631

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.001 per share | CLSD | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 1.03. Bankruptcy or Receivership.
On November 23, 2025, Clearside Biomedical, Inc. (the "**Company**") filed a voluntary petition (Case No. 25-12109) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the "**Court**" and such case, the "**Case**"). The Company will continue to operate its business as a "debtor-in-possession" under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. To ensure its ability to continue operating in the ordinary course of business, the Company has filed with the Court motions seeking a variety of "first-day" relief (collectively, the "**First Day Motions**"). The Company's objective in the Case is to consummate a sale of substantially all of its assets to the highest bidder. Additional information about the Case, including access to Court documents, is available online at <u>https://dm.epiq11.com/ClearsideBiomedical</u>, a website administered by Epiq Bankruptcy Solutions LLC, a third-party bankruptcy claims and noticing agent. The information on this website is not incorporated by reference into, and does not constitute part of, this Current Report on Form 8-K.

#### Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 24, 2025, the Company received written notice (the "**Delisting Notice**") from the staff of The Nasdaq Stock Market LLC ("**Nasdaq**") notifying the Company that, as a result of the Case and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq has determined that the Company's common stock, par value $0.001 per share (the "**Common Stock**"), will be delisted from Nasdaq. In addition, as previously disclosed, on August 28, 2025, the Company received written notice (the "**MVLS Notice**") from Nasdaq notifying the Company that it is not in compliance with the minimum Market Value of Listed Securities of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A). In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq, specifically referencing that certain MVLS Notice.

Trading of the Common Stock will be suspended at the opening of business on December 1, 2025 and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "**SEC**"), which will remove the Common Stock from listing on Nasdaq. The Delisting Notice also indicated that the Company may appeal Nasdaq's determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

The Company does not intend to appeal the determination and, therefore, it is expected that the Common Stock will be delisted. As a result, the Common Stock is expected to begin trading exclusively on the over-the-counter ("**OTC**") market on December 1, 2025. On the OTC market, shares of the Common Stock, which previously traded on Nasdaq under the symbol CLSD is expected to trade under the symbol CLSDQ.

#### Item 7.01. Regulation FD Disclosure.
On November 24, 2025, the Company issued a press release announcing that it had entered into the Case. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended (the "**Exchange Act**"), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

#### Item 9.01. Financial Statements and Exhibits
(d) *Exhibits*

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | [Press Release Dated November 24, 2025](d41251dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: November 25, 2025 | **CLEARSIDE BIOMEDICAL, INC.** | **CLEARSIDE BIOMEDICAL, INC.** |
|  | By: | /s/ Charles A. Deignan |
|  | Name: | Charles A. Deignan |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g41251g1125121304638.jpg)

**Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process** 

*- Intended to Maximize Stakeholder Value Through Structured Process -* 

*- Validated SCS Microinjector<sup>®</sup> Delivery Platform Anchored by* 

*Commercial Product and Five Suprachoroidal Licensing Collaborations* 

*with Future Royalty Revenue Potential -* 

*- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD* 

*and Path for Phase 2b/3 Trial in Diabetic Retinopathy -* 

*- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema -* 

ALPHARETTA, Ga., November 24, 2025 — Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS<sup>®</sup>), announced today that it has filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. As part of the case, Clearside also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures, if approved by the court, would require interested parties to submit binding offers to acquire Clearside's assets in whole or in part, which would be purchased free and clear of liens and interests.

"Our Board of Directors and management team have thoroughly assessed all of our strategic options and believe that this Chapter 11 structured process represents the best possible option for Clearside and its stakeholders," said George Lasezkay, PharmD, JD, President and Chief Executive Officer. "We believe that we have attractive assets based on our clinically proven SCS Microinjector<sup>®</sup> platform and associated intellectual property, our successful suprachoroidal CLS-AX (axitinib injectable suspension) clinical development program, multiple suprachoroidal licensing agreements and other related assets."

Clearside has filed a series of motions with the court seeking to ensure the continuation of normal operations during this process. Additional information about this process and proposed asset auction and sale, as well as other documents related to the restructuring and reorganization proceedings, is available through Clearside's claims agent, Epiq Bankruptcy Solutions LLC, at <u>https://dm.epiq11.com/ClearsideBiomedical</u>.

------

The petition was filed in United States Bankruptcy Court for the District of Delaware, Case No. 25-12109.

**Advisors** 

Cooley LLP and Richards, Layton & Finger, P.A. are serving as legal counsel and Berkeley Research Group LLC (BRG) is serving as financial restructuring advisor to Clearside.

**<u>Company Highlights</u>**

**SCS Injection Platform:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The SCS Microinjector is a proven in-office, repeatable, non-surgical procedure for the targeted delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clearside has a pipeline of small molecule product candidates for administration via the SCS Microinjector, and
commercial scale manufacturing capability for the SCS Microinjector that includes ISO certification and CE mark certification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clearside successfully navigated the U.S. Food & Drug Administration ("FDA") drug/device
regulatory pathway to obtain commercial approval for its first product, XIPERE<sup>®</sup> (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of uveitic macular
edema.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A permanent CPT code is assigned in the United States for suprachoroidal injections potentially enabling
physicians to receive higher reimbursement for administering any drug into the SCS versus the reimbursement of the current practice of injecting drugs into the vitreous.

**Internal Pipeline - CLS-AX Program:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• CLS-AX (axitinib injectable suspension) is a proprietary suspension of
axitinib for suprachoroidal injection. CLS-AX is being developed for the treatment of serious back of the eye diseases including neovascular age-related macular
degeneration (wet AMD) and diabetic retinopathy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Suprachoroidal injection of CLS-AX has demonstrated meaningful potential
in Phase 1/2a and Phase 2b wet AMD clinical trials. These data support the potential efficacy, safety and versatility of CLS-AX to treat this chronic disease.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clearside conducted a successful End-of-Phase 2 meeting with the FDA and gained alignment on the essential components of a potential Phase 3 program in wet AMD designed to provide dosing flexibility
similar to the current standard of care anti-VEGF biologics with the extended durability of a tyrosine kinase inhibitor (TKI). Clearside has also developed a Phase 2b/3 clinical trial design for CLS-AX in
diabetic retinopathy.

**Internal Pipeline – Preclinical Small Molecule Programs:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clearside is evaluating preclinical data on two approaches targeting Geographic Atrophy (GA) – improving
choroidal perfusion and modulating pro-inflammatory cells. Delivery of small molecules via suprachoroidal injection enables comprehensive drug coverage of both the retina and choroid, while also potentially
minimizing systemic and anterior segment side effects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clearside is evaluating preclinical data on the combination of a steroid plus a TKI (axitinib formulation) for
the treatment of Diabetic Macula Edema (DME), the most common cause of vision loss in individuals with diabetes.

**External Licensing Agreements:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clearside strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic
agents including gene therapies and anti-tumor agents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clearside's innovative SCS Microinjector is being used in commercial ophthalmic products and clinical
development programs by Aura Biosciences, Bausch + Lomb, BioCryst Pharmaceuticals, REGENXBIO and its global partner AbbVie, and Arctic Vision and its commercial partner Santen.

**Royalty Sub:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In connection with a Purchase and Sale Agreement (the "Purchase and Sale Agreement") entered into in
August 2022 between Clearside Royalty LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Royalty Sub") and entities managed by HealthCare Royalty Management, LLC ("HCR"), Royalty Sub
received from the Company, and subsequently sold to HCR, certain rights to receive royalty and milestone payments payable to the Company under existing license agreements related to XIPERE (triamcinolone acetonide injectable suspension) or the
Company's SCS Microinjector technology (collectively, the "Royalties").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Assets available for sale related to the Royalty Sub include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Equity in Clearside Royalty LLC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Right to revenue from the Royalties after reaching the revenue cap on Royalties purchased by HCR of
$106.5 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Rights to CLS-AX and its other pre-clinical programs.

------

**About Clearside's Suprachoroidal Space (SCS<sup>®</sup>) Injection Platform and SCS Microinjector<sup>®</sup>** 

Clearside's suprachoroidal delivery platform is designed to enable targeted treatment for multiple retinal diseases, including neovascular age-related macular degeneration (wet AMD), diabetic retinopathy, diabetic macular edema, geographic atrophy and ocular cancer. The Company's patent protected, proprietary suprachoroidal space (SCS<sup>®</sup>) injection treatment approach offers unprecedented access to the back of the eye, where sight-threatening disease often occurs. Clearside's patented SCS Microinjector<sup>®</sup> can deliver a wide variety of drug candidates into the suprachoroidal space, providing targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. The SCS Microinjector is comprised of a syringe with a custom-designed hub and two 30-gauge hollow microneedles of varying lengths, each approximately one millimeter, optimizing insertion and suprachoroidal administration of drugs.

**About XIPERE<sup>®</sup> (triamcinolone acetonide injectable suspension) for suprachoroidal use** 

XIPERE<sup>®</sup> (triamcinolone acetonide injectable suspension) for suprachoroidal use is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis. XIPERE is approved by the U.S. Food and Drug Administration and is commercially available in the United States. Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, has the exclusive license for the commercialization and development of XIPERE in the U.S. and Canada. Arctic Vision, a specialty ophthalmology company based in China, has the exclusive license for the commercialization and development of XIPERE, which they refer to as Arcatus<sup>®</sup>, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries. A link to the full prescribing information is available at <u>https://www.xipere.com/hcp/#isi</u>.

**About CLS-AX (axitinib injectable suspension)** 

Clearside's lead development asset, CLS-AX (axitinib injectable suspension), is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet formulation to treat advanced renal cell carcinoma, that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. Clearside believes this broad VEGF blockade may have efficacy advantages over existing retinal therapies by acting at a different level of the angiogenesis cascade and may benefit patients who sub-optimally respond to current, more narrowly focused anti-VEGF therapies.

------

With suprachoroidal administration of axitinib, there is the potential to achieve prolonged duration and targeted delivery to affected tissue layers by compartmentalizing axitinib behind the retina, thereby limiting drug exposure to the front of the eye. Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated positive results in Phase 1/2a and Phase 2b wet AMD clinical trials in which CLS-AX was well tolerated and demonstrated a positive safety profile. Clearside has aligned with the U.S. Food and Drug Administration (FDA) on the design of a potential Phase 3 trial in wet AMD and has also developed a streamlined Phase 2b/3 trial design in non-proliferative diabetic retinopathy.

**About Clearside Biomedical, Inc.** 

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS<sup>®</sup>) to improve patient outcomes. Clearside's SCS injection platform, utilizing the Company's patented SCS Microinjector<sup>®</sup>, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside has a pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, <u>CLS-AX (axitinib injectable suspension)</u>, is a Phase 3 ready asset for the treatment of neovascular age-related macular degeneration (wet AMD). Clearside developed and gained approval for its first product, <u>XIPERE<sup>®</sup> (triamcinolone acetonide injectable suspension)</u> for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit <u>clearsidebio.com</u> or follow us on <u>LinkedIn</u> and <u>X</u>.

**Cautionary Note Regarding Forward-Looking Statements** 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and are based on Clearside's current beliefs and expectations. These forward-looking statements include statements regarding: the board of director's and management's belief that Chapter 11 represents the best possible option for Clearside and its stakeholders; expectations relating to the auction and sale process, and related bidding procedures; the clinical development of Clearside's product candidates, including CLS-AX and the potential Phase 3 trial design; the potential benefits of CLS-AX, Clearside's suprachoroidal delivery technology and Clearside's SCS Microinjector<sup>®</sup>; and pipeline expansion opportunities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and

------

uncertainties that may cause actual results to differ materially include: the approval by the court of Clearside's first day motions; risks and uncertainties regarding Clearside's ability to successfully consummate and complete a plan of reorganization under Chapter 11; risks associated with the potential adverse impact of the bankruptcy proceedings on Clearside's business, financial condition, liquidity and results of operations; Clearside's ability to maintain contracts that are critical to expected limited operations and meet financial obligations during the bankruptcy proceedings; the outcome and timing of the bankruptcy process and any potential sale of all or some of Clearside's assets; the effect of the filing of bankruptcy and any potential sale of all or some of Clearside's assets on its relationships with third parties; Clearside's expectations regarding liquidity and obligations, including its use of, and need for, cash and any other underlying assumptions; the length of time that Clearside will operate under Chapter 11 and the continued availability of operating capital during such pendency; the impact of the Chapter 11 case on the trading price and volatility of Clearside's common stock and the possible delisting of Clearside's common stock; any potential proceedings that may be brought by third parties in connection with the bankruptcy petitions or the potential sale of all or some of Clearside's assets; uncertainty regarding obtaining the bankruptcy court's approval of the potential sale of all or some of Clearside's assets or other terms and conditions to any such potential sale; Clearside's ability to negotiate and obtain any financing, including debtor in possession funding, with lenders or creditors during the Chapter 11 case and to comply with the restrictions imposed by the terms and conditions of the potential financing arrangements, if any; the timing or amount of any distributions, if any, to Clearside's stakeholders; Clearside's ability to retain senior management and other key personnel during the pendency of the Chapter 11 case; uncertainties inherent in the conduct of clinical trials, Clearside's reliance on third parties over which it may not always have full control, Clearside's ability to raise additional capital, and other risks and uncertainties that are described in Clearside's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2025, Clearside's Quarterly Report on Form 10-Q filed with the SEC on August 8, 2025 and Clearside's other periodic reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

**Investor and Media Contact:** 

<u>ir@clearsidebio.com</u> 

Source: Clearside Biomedical, Inc.